Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı
Yıl: 2016 Cilt: 44 Sayı: Suppl. 3 Sayfa Aralığı: 1 - 7 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı
Öz: Koroner arter hastalığı (KAH), gelişmiş ülkelerdeki mortalite ve morbiditenin önemli nedenlerindendir. Dünyada son dört dekadda KAH mortalite oranları azalmış olmakla birlikte kararlı KAH (KKAH), klinik izlemde önemli bir durum olmaya devam etmektedir. Bu yazıda, KKAH'nın epidemi-yolojisi ve tedavi stratejileri önemli kılavuzlar doğrultusunda özetlenmiştir.
Anahtar Kelime: Konular:
Stable coronary heart disease: Epidemiology and the current treatment guidelines
Öz: Coronary heart disease (CHD) is a major cause of mortality and morbidity in developed countries. Although CHD mortality rates worldwide have declined over the past 4 decades, stable CHD remains an important condition for clinical management. In this article, epidemiology and management strategies for stable CHD were summarized according to the major guidelines
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007;26:38-48.
- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:948-54.
- National Institutes of Health NH, Lung and Blood Institute. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart, Lung and Blood Institute; 2012.
- Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001;141:735-41.
- Han SH, Bae JH, Holmes DR Jr, Lennon RJ, Eeckhout E, Barsness GW, et al. Sex differences in atheroma burden and endothelial function in patients with early coronary athero- sclerosis. Eur Heart J 2008;29:1359-69.
- Elveback LR, Connolly DC. Coronary heart disease in resi- dents of Rochester, Minnesota. V. Prognosis of patients with coronary heart disease based on initial manifestation. Mayo Clin Proc 1985;60:305-11.
- Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol. 1972;29:154-63.
- Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, et al. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-spon- sored Women's Ischemia Syndrome Evaluation. Circulation 2006;114:894-904.
- Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/ STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Associa- tion Task Force on Practice Guidelines, and the American Col- lege of Physicians, American Association for Thoracic Sur- gery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and So- ciety of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44- e164.
- Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the manage- ment of stable coronary artery disease of the European Soci- ety of Cardiology. Eur Heart J 2013;34:2949-3003.
- Frishman WH, Heiman M, Soberman J, Greenberg S, Eff J. Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. Am J Cardiol 1991;67:665-70.
- Narahara KA. Double-blind comparison of once daily be- taxolol versus propranolol four times daily in stable an- gina pectoris. Betaxolol Investigators Group. Am J Cardiol 1990;65:577-82.
- Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) Eur Heart J 1996;17:76-81.
- Steffensen R, Grande P, Pedersen F, Haunsİ S. Effects of at- enolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int J Cardiol 1993;40:143-53.
- Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wa- gener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised con- trolled trial. Lancet 2004;364:849-57.
- Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Gar- za D, et al. Effect of antihypertensive agents on cardiovascu- lar events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25.
- Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic se- vere angina. J Am Coll Cardiol 2004;43:1375-82.
- DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004;64:1757-65.
- Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994;37:279-88.
- IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-75.
- Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010 Jun 19;375:2161-7.
- Collaborative overview of randomised trials of antiplate- let therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various cat- egories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
- Antithrombotic Trialists' Collaboration. Collaborative meta- analysis of randomised trials of antiplatelet therapy for pre- vention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
- Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sİrensen S, Omblus R. Double-blind trial of aspirin in primary preven- tion of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39.
- Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
- Shah SA, Shapiro RJ, Mehta R, Snyder JA. Impact of en- hanced external counterpulsation on Canadian Cardiovascular Society angina class in patients with chronic stable angina: a meta-analysis. Pharmacotherapy 2010;30:639-45.
- Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascu- larization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the Europe- an Association for Cardio-Thoracic Surgery (EACTS)Devel- oped with the special contribution of the European Associa- tion of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619.
| APA | yavuzgil o (2016). Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. , 1 - 7. |
| Chicago | yavuzgil oğuz Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. (2016): 1 - 7. |
| MLA | yavuzgil oğuz Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. , 2016, ss.1 - 7. |
| AMA | yavuzgil o Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. . 2016; 1 - 7. |
| Vancouver | yavuzgil o Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. . 2016; 1 - 7. |
| IEEE | yavuzgil o "Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı." , ss.1 - 7, 2016. |
| ISNAD | yavuzgil, oğuz. "Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı". (2016), 1-7. |
| APA | yavuzgil o (2016). Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. Türk Kardiyoloji Derneği Arşivi, 44(Suppl. 3), 1 - 7. |
| Chicago | yavuzgil oğuz Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. Türk Kardiyoloji Derneği Arşivi 44, no.Suppl. 3 (2016): 1 - 7. |
| MLA | yavuzgil oğuz Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. Türk Kardiyoloji Derneği Arşivi, vol.44, no.Suppl. 3, 2016, ss.1 - 7. |
| AMA | yavuzgil o Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. Türk Kardiyoloji Derneği Arşivi. 2016; 44(Suppl. 3): 1 - 7. |
| Vancouver | yavuzgil o Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı. Türk Kardiyoloji Derneği Arşivi. 2016; 44(Suppl. 3): 1 - 7. |
| IEEE | yavuzgil o "Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı." Türk Kardiyoloji Derneği Arşivi, 44, ss.1 - 7, 2016. |
| ISNAD | yavuzgil, oğuz. "Kararlı koroner arter hastalığı: Epidemiyoloji ve güncel tedavi kılavuzlarının yaklaşımı". Türk Kardiyoloji Derneği Arşivi 44/Suppl. 3 (2016), 1-7. |
